Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.32 |
| ▸ | MEN1 | O00255 | 2/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | CNR2 | P34972 | 3/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | KCNK3 | O14649 | 1/20 | 0.32 |
| ▸ | THRB | P10828 | 1/20 | 0.32 |
| ▸ | BLM | P54132 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | CNR1 | P21554 | 2/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10000757 | 0.78 | FASN (0.32) | — | |
| SCHEMBL12367168 | 0.73 | PTGS2 (0.35) | PTGS2KMT2AMEN1NPC1RAB9A | |
| SCHEMBL10000755 | 0.73 | CA1 (0.31) | KMT2A | |
| SCHEMBL10000754 | 0.72 | AKR1B1 (0.36) | KMT2AMEN1ALDH1A1POLBCYP1A2 | |
| SCHEMBL4342682 | 0.67 | CNR2 (0.44) | CNR2ALDH1A1KCNK3THRBBLM | |
| SCHEMBL14562205 | 0.66 | HPGD (0.58) | KMT2AMEN1NPC1RAB9ACNR2 | |
| SCHEMBL8681480 | 0.65 | CNR2 (0.51) | KMT2AMEN1CNR2ALDH1A1KCNK3 | |
| SCHEMBL12744505 | 0.64 | ERBB2 (0.40) | ALDH1A1 | |
| SCHEMBL3007152 | 0.64 | POLB (0.71) | KMT2AMEN1CNR2ALDH1A1POLB | |
| SCHEMBL3007157 | 0.64 | POLB (0.71) | KMT2AMEN1CNR2ALDH1A1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8207229-B1 | Preparation of hydroquinone amide compounds with antioxidant properties | CATALYS SAS (FR) | 2012-06-26 | — | — | US | disclosed |
| US-8003824-B2 | Preparation of hydroquinone amide compounds with antioxidant properties | CATALYS SAS (FR) | 2011-08-23 | — | — | US | disclosed |
| US-20110021820-A1 | Preparation of Hydroquinone Amide Compounds with Antioxidant Properties | CATALYS SAS (FR) | 2011-01-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110021820-A1 | Preparation of Hydroquinone Amide Compounds with Antioxidant Properties | NQO1, TYR, AHR | PTGS2 540/4885KMT2A 1182/4885MEN1 4515/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.